Pharmacogenetics and anaesthesia: The value of genetic profiling

Anaesthesia

Volumn 67, Issue 2, 2012, Pages 165-179

  Landau, R ^a   Bollag, L A ^a   Kraft, J C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; MERCAPTOPURINE; METOPROLOL; MITOCHONDRIAL DNA; MORPHINE; NUCLEOTIDE; OXYCODONE; RNA; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; WARFARIN;

ALLELE; ANESTHESIA; ANESTHESIST; CODON; DRUG METABOLISM; EPIGENETICS; GENE EXPRESSION PROFILING; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; GENOMICS; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MORTALITY; OUTCOME ASSESSMENT; PAIN; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TREATMENT OUTCOME;

ANESTHESIA; ANESTHETICS; GENETIC TESTING; HISTORY, 20TH CENTURY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84855991764     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2011.06918.x     Document Type: Review

References (167)

1. Weber WW,. Pharmacogenetics. New York: Oxford University Press, 1997.
2. Pauling L, Itano HA, et al., Sickle cell anemia, a molecular disease. Science 1949; 109: 443.
3. Motulsky AG,. Drug reactions enzymes, and biochemical genetics. Journal of the Ameircan Medical Association 1957; 165: 835-7.
4. Vogel F,. Moderne Probem der Humangenetik. Ergebnisse der Inner Medizine und Kinderheilk 1959; 12: 52-125.
5. Kalow W,. Pharmacogenetics; Heredity and the Response to Drugs. Philadelphia: W.B. Saunders Co., 1962.
6. Lehmann H, Ryan E,. The familial incidence of low pseudocholinesterase level. Lancet 1956; 271: 124.
7. Kalow W, Gunn DR,. The relation between dose of succinylcholine and duration of apnea in man. The Journal of Pharmacology and Experimental Therapeutics 1957; 120: 203-14.
8. The human genome. Science genome map. Science 2001; 291: 1218.
9. Venter JC, Adams MD, Myers EW, et al., The sequence of the human genome. Science 2001; 291: 1304-51. (Pubitemid 32173090)
10. Collins FS, Morgan M, Patrinos A,. The Human Genome Project: lessons from large-scale biology. Science 2003; 300: 286-90. (Pubitemid 36433711)
11. http://www.pharmgkb.org (accessed 25/06/2011).
12. Flockhart DA, Skaar T, Berlin DS, et al., Clinically available pharmacogenomics tests. Clinical Pharmacology and Therapeutics 2009; 86: 109-13.
13. Frueh FW, Amur S, Mummaneni P, et al., Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008; 28: 992-8.
14. Sim SC, Ingelman-Sundberg M,. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends in Pharmacological Sciences 2011; 32: 72-81.
15. Allen PD,. Anesthesia and the human genome project: the quest for accurate prediction of drug responses. Anesthesiology 2005; 102: 494-5. (Pubitemid 40315135)
16. Ama T, Bounmythavong S, Blaze J, et al., Implications of pharmacogenomics for anesthesia providers. American Association of Nurse Anesthetists Journal 2010; 78: 393-9.
17. Avram MJ, Gupta DK, Atkinson AJ Jr,. Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum. Clinical Pharmacology and Therapeutics 2008; 84: 3-6. (Pubitemid 351861512)
18. Bukaveckas BL, Valdes R Jr, Linder MW,. Pharmacogenetics as related to the practice of cardiothoracic and vascular anesthesia. Journal of Cardiothoracic and Vascular Anesthesia 2004; 18: 353-65. (Pubitemid 38844756)
19. Galinkin JL, Demmer L, Yaster M,. Genetics for the pediatric anesthesiologist: a primer on congenital malformations, pharmacogenetics, and proteomics. Anesthesia and Analgesia 2010; 111: 1264-74.
20. Galley HF, Mahdy A, Lowes DA,. Pharmacogenetics and anesthesiologists. Pharmacogenomics 2005; 6: 849-56. (Pubitemid 41724358)
21. Iohom G, Fitzgerald D, Cunningham AJ,. Principles of pharmacogenetics- implications for the anaesthetist. British Journal of Anaesthesia 2004; 93: 440-50. (Pubitemid 39206908)
22. Kim H, Clark D, Dionne RA,. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. Journal of Pain 2009; 10: 663-93.
23. Kosarac B, Fox AA, Collard CD,. Effect of genetic factors on opioid action. Current Opinion in Anesthesiology 2009; 22: 476-82.
24. Landau R,. Pharmacogenetic influences in obstetric anaesthesia. Best Practice and Research. Clinical Obstetrics and Gynaecology 2010; 24: 277-87.
25. Landau R, Kraft JC,. Pharmacogenetics in obstetric anesthesia. Current Opinion in Anesthesiology 2010; 23: 323-9.
26. Palmer SN, Giesecke NM, Body SC, et al., Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 2005; 102: 663-71. (Pubitemid 40315159)
27. Schwinn DA, Podgoreanu M,. Pharmacogenomics and end-organ susceptibility to injury in the perioperative period. Best Practice and Research. Clinical Anaesthesiology 2008; 22: 23-37. (Pubitemid 351418964)
28. Searle R, Hopkins PM,. Pharmacogenomic variability and anaesthesia. British Journal of Anaesthesia 2009; 103: 14-25.
29. Sweeney BP,. Pharmacogenomics and anaesthesia: explaining the variability in response to opiates. European Journal of Anaesthesiology 2007; 24: 209-12.
30. Relling MV, Klein TE,. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology and Therapeutics. 2011; 89: 464-7.
31. Relling MV, Gardner EE, Sandborn WJ, et al., Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clinical Pharmacology and Therapeutics. 2011; 89: 387-91.
32. http://www.cypalleles.ki.se/ (accessed 25/06/2011).
33. Cascorbi I,. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. European Journal of Clinical Investigation 2003; 33 (Suppl. 2): 17-22.
34. Kirchheiner J, Schmidt H, Tzvetkov M, et al., Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Journal of Pharmacogenomics 2007; 7: 257-65. (Pubitemid 47202488)
35. Koren G, Cairns J, Chitayat D, et al., Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704. (Pubitemid 44223697)
36. Ferner RE,. Did the drug cause death? Codeine and breastfeeding. Lancet 2008; 372: 606-8.
37. Madadi P, Ross CJ, Hayden MR, et al., Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clinical Pharmacology and Therapeutics 2009; 85: 31-5.
38. Willmann S, Edginton AN, Coboeken K, et al., Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clinical Pharmacology and Therapeutics 2009; 86: 634-43.
39. Ciszkowski C, Madadi P, Phillips MS, et al., Codeine, ultrarapid-metabolism genotype, and postoperative death. New England Journal of Medicine 2009; 361: 827-8.
40. Gasche Y, Daali Y, Fathi M, et al., Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New England Journal of Medicine 2004; 351: 2827-31. (Pubitemid 40051906)
41. US-FDA. Information for Healthcare Professionals: Use of Codeine Products in Nursing Mothers-17 August 2007. (accessed 2/11/2011).
42. de Leon J, Susce MT, Murray-Carmichael E,. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Molecular Diagnosis and Therapy 2006; 10: 135-51. (Pubitemid 43974591)
43. Lenz H, Sandvik L, Qvigstad E, et al., A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesthesia and Analgesia 2009; 109: 1279-83.
44. Gimbel J, Ahdieh H,. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesthesia and Analgesia 2004; 99: 1472-7. (Pubitemid 39407301)
45. Olkkola KT, Hagelberg NM,. Oxycodone: new 'old' drug. Current Opinion in Anesthesiology 2009; 22: 459-62.
46. Cone EJ, Darwin WD, Buchwald WF, et al., Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug and Metabolism Disposition 1983; 11: 446-50. (Pubitemid 13021124)
47. Lalovic B, Kharasch E, Hoffer C, et al., Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology and Therapeutics 2006; 79: 461-79.
48. Gronlund J, Saari TI, Hagelberg NM, et al., Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clinical Drug Investigation 2011; 31: 143-53.
49. Kummer O, Hammann F, Moser C, et al., Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. European Journal of Clinical Pharmacology 2011; 67: 63-71.
50. Nieminen TH, Hagelberg NM, Saari TI, et al., Grapefruit juice enhances the exposure to oral oxycodone. Basic Clinical Pharmacology and Toxicology 2010; 107: 782-8.
51. Samer CF, Daali Y, Wagner M, et al., The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology 2010; 160: 907-18.
52. Gronlund J, Saari TI, Hagelberg N, et al., Miconazole oral gel increases the exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrobial Agents and Chemotherapy. 2011; 55: 1063-7.
53. Gronlund J, Saari TI, Hagelberg NM, et al., Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. British Journal of Clinical Pharmacology 2010; 70: 78-87.
54. Lemberg KK, Siiskonen AO, Kontinen VK, et al., Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia. Anesthesia and Analgesia 2008; 106: 463-70. (Pubitemid 351156669)
55. Heiskanen T, Olkkola KT, Kalso E,. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clinical Pharmacology and Therapeutics 1998; 64: 603-11. (Pubitemid 29011380)
56. Maddocks I, Somogyi A, Abbott F, et al., Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of Pain and Symptom Management 1996; 12: 182-9. (Pubitemid 26269244)
57. Susce MT, Murray-Carmichael E, de Leon J,. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006; 30: 1356-8. (Pubitemid 44216064)
58. de Leon J, Dinsmore L, Wedlund P,. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. Journal of Clinical Psychopharmacology 2003; 23: 420-1. (Pubitemid 36951190)
59. Samer CF, Daali Y, Wagner M, et al., Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. British Journal of Pharmacology 2010; 160: 919-30.
60. Saari TI, Gronlund J, Hagelberg NM, et al., Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. European Journal of Clinical Pharmacology 2010; 66: 387-97.
61. Nielsen CS, Staud R, Price DD,. Individual differences in pain sensitivity: measurement, causation, and consequences. Journal of Pain 2009; 10: 231-7.
62. Foulkes T, Wood JN,. Pain genes. PLoS Genetics 2008; 4: e1000086.
63. Stamer UM, Zhang L, Stuber F,. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11: 843-64.
64. Walter C, Lotsch J,. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146: 270-5.
65. Doehring A, Geisslinger G, Lotsch J,. Epigenetics in pain and analgesia: an imminent research field. European Journal of Pain 2011; 15: 11-6.
66. Mata M, Fink DJ,. Gene therapy for pain. Anesthesiology 2007; 106: 1079-80. (Pubitemid 46828155)
67. Mata M, Hao S, Fink DJ,. Applications of gene therapy to the treatment of chronic pain. Current Gene Therapy 2008; 8: 42-8. (Pubitemid 351485839)
68. Wolfe D, Wechuck J, Krisky D, et al., A clinical trial of gene therapy for chronic pain. Pain Medicine 2009; 10: 1325-30.
69. Lotsch J, Geisslinger G,. Pharmacogenetics of new analgesics. British Journal of Pharmacology 2011; 163: 447-60.
70. Budnitz DS, Pollock DA, Weidenbach KN, et al., National surveillance of emergency department visits for outpatient adverse drug events. Journal of the American Medical Association 2006; 296: 1858-66. (Pubitemid 44596195)
71. Wester K, Jonsson AK, Spigset O, et al., Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology 2008; 65: 573-9. (Pubitemid 351365134)
72. Wysowski DK, Nourjah P, Swartz L,. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Archives of Internal Medicine 2007; 167: 1414-9. (Pubitemid 47052441)
73. Aithal GP, Day CP, Kesteven PJ, et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9. (Pubitemid 29103806)
74. D'Andrea G, D'Ambrosio RL, Di Perna P, et al., A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9. (Pubitemid 40070748)
75. Higashi MK, Veenstra DL, Kondo LM, et al., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Journal of the American Medical Association 2002; 287: 1690-8. (Pubitemid 34289221)
76. Rost S, Fregin A, Ivaskevicius V, et al., Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41. (Pubitemid 38209110)
77. Takahashi H, Echizen H,. Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics 2001; 40: 587-603. (Pubitemid 32758581)
78. Wadelius M, Sorlin K, Wallerman O, et al., Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics Journal 2004; 4: 40-8. (Pubitemid 38256604)
79. Rieder MJ, Reiner AP, Gage BF, et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine 2005; 352: 2285-93. (Pubitemid 40740552)
80. Limdi NA, Wadelius M, Cavallari L, et al., Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115: 3827-34.
81. Borgiani P, Ciccacci C, Forte V, et al., CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10: 261-6.
82. Caldwell MD, Awad T, Johnson JA, et al., CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-12.
83. Perez-Andreu V, Roldan V, Anton AI, et al., Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977-9.
84. Ross KA, Bigham AW, Edwards M, et al., Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. Journal of Human Genetics 2010; 55: 582-9.
85. McDonald MG, Rieder MJ, Nakano M, et al., CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Molecular Pharmacology 2009; 75: 1337-46.
86. Takeuchi F, McGinnis R, Bourgeois S, et al., A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genetics 2009; 5: e1000433.
87. Sconce EA, Khan TI, Wynne HA, et al., The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33. (Pubitemid 41510803)
88. Gage BF, Lesko LJ,. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of Thrombosis and Thrombolysis 2008; 25: 45-51.
89. US-FDA. Coumadin (warfarin sodium) Tablet and Injection: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)-January 2010; (accessed 28/01/2011).
90. Finkelman BS, Gage BF, Johnson JA, et al., Genetic warfarin dosing tables versus algorithms. Journal of the American College of Cardiology 2011; 57: 612-8.
91. French B, Joo J, Geller NL, et al., Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010; 11: 108.
92. Gage BF, Eby C, Johnson JA, et al., Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics 2008; 84: 326-31.
93. Klein TE, Altman RB, Eriksson N, et al., Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine 2009; 360: 753-64.
94. Le Cam-Duchez V, Fretigny M, Cailleux N, et al., Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets. Thrombosis Research 2010; 126: e235-7.
95. Lenzini P, Wadelius M, Kimmel S, et al., Integration of genetic, clinical, and INR data to refine warfarin dosing. Clinical Pharmacology and Therapeutics 2010; 87: 572-8.
96. Moreau C, Pautas E, Gouin-Thibault I, et al., Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. Journal of Thrombosis and Haemostasis. 2011; 9: 711-8.
97. Sagreiya H, Berube C, Wen A, et al., Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenetics and Genomics 2010; 20: 407-13.
98. Shin J, Cao D,. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2010; 12: 125-34.
99. Conti R, Veenstra DL, Armstrong K, et al., Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision Making 2010; 30: 328-40.
100. Eckman MH, Rosand J, Greenberg SM, et al., Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Annals of Internal Medicine 2009; 150: 73-83.
101. Leey JA, McCabe S, Koch JA, et al., Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. American Journal of Geriatric Pharmacotherapy 2009; 7: 197-203.
102. Patrick AR, Avorn J, Choudhry NK,. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes 2009; 2: 429-36.
103. Rosove MH, Grody WW,. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Annals of Internal Medicine 2009; 151: 270-3, W95.
104. Tan GM, Wu E, Lam YY, et al., Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010; 11: 439-48.
105. Gandara E, Wells PS,. Will there be a role for genotyping in warfarin therapy? Current Opinion in Hematology 2010; 17: 439-43.
106. Meckley LM, Gudgeon JM, Anderson JL, et al., A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010; 28: 61-74.
107. Sofi F, Marcucci R, Gori AM, et al., Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thrombosis and Haemostasis 2010; 103: 841-8.
108. Shuldiner AR, O'Connell JR, Bliden KP, et al., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Journal of the American Medical Association 2009; 302: 849-57.
109. Sofi F, Giusti B, Marcucci R, et al., Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics Journal 2011; 11: 199-206.
110. Mega JL, Simon T, Collet JP, et al., Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Journal of the American Medical Association 2010; 304: 1821-30.
111. US-FDA. FDA Drug Safety Communication: Reduced Effectiveness of Plavix (clopidogrel) in Patients who are Poor Metabolizers of the Drug-March 2010. (accessed 08/02/2011).
112. Gilard M, Arnaud B, Cornily JC, et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. Journal of the American College of Cardiology 2008; 51: 256-60.
113. Gilard M, Arnaud B, Le Gal G, et al., Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. Journal of Thrombosis and Haemostasis 2006; 4: 2508-9. (Pubitemid 44575451)
114. Roden DM, Stein CM,. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 2009; 119: 2127-30.
115. Kreutz RP, Stanek EJ, Aubert R, et al., Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30: 787-96.
116. Simon T, Verstuyft C, Mary-Krause M, et al., Genetic determinants of response to clopidogrel and cardiovascular events. New England Journal of Medicine 2009; 360: 363-75.
117. US-FDA. Information on Clopidogrel Bisulfate (marketed as Plavix)-October 2010; (accessed 08/02/2011).
118. Andersen SS, Hansen ML, Gislason GH, et al., Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction. Cardiology 2009; 112: 144-50.
119. 1- adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Medicine 2003; 9: 1300-5. (Pubitemid 37279854)
120. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. Journal of Biology and Chemistry 2002; 277: 30429-35. (Pubitemid 34970733)
121. 1 adrenergic receptor affect agonist-promoted trafficking. Journal of Cardiovascular Pharmacology 2002; 39: 155-60. (Pubitemid 34093534)
122. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414-9. (Pubitemid 24272896)
123. 2-adrenergic receptor on agonist-mediated vascular desensitization. New England Journal of Medicine 2001; 345: 1030-5.
124. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. Journal of Biology and Chemistry 1993; 268: 23116-21. (Pubitemid 23328021)
125. 2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 2004; 14: 517-22. (Pubitemid 39100003)
126. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB,. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. Journal of Biology and Chemistry 2000; 275: 23059-64. (Pubitemid 30646196)
127. 1- adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11: 191-7. (Pubitemid 32319868)
128. 2- adrenoceptor polymorphisms and cardiovascular diseases. British Journal of Pharmacology 2009; 158: 61-9.
129. 1- adrenergic receptor is associated with the cardiovascular response to metoprolol. Clinical Pharmacology and Therapeutics 2003; 74: 372-9. (Pubitemid 37222858)
130. 1-adrenergic receptor polymorphisms in heart failure. Heart Failure Clinics 2010; 6: 27-33.
131. 1- adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade. Clinical Pharmacology and Therapeutics 2003; 73: 366-71. (Pubitemid 36403596)
132. 1-adrenergic receptor blockade in patients with essential hypertension. Clinical Cardiology 2004; 27: 347-50. (Pubitemid 38703089)
133. 1-adrenoceptor does not influence blood pressure or heart rate response to β-blockade in hypertensive subjects. Clinical Science (London) 2000; 99: 233-8.
134. 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clinical Pharmacology and Therapeutics 2003; 74: 44-52. (Pubitemid 36776175)
135. Filigheddu F, Argiolas G, Degortes S, et al., Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 2010; 11: 319-25.
136. 1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European Journal of Heart Failure 2003; 5: 463-8. (Pubitemid 37021640)
137. de Groote P, Lamblin N, Helbecque N, et al., The impact of β-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. European Journal of Heart Failure 2005; 7: 966-73. (Pubitemid 41443589)
138. 1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to β-blocker therapy. Pharmacogenetics and Genomics 2005; 15: 227-34. (Pubitemid 40569894)
139. 1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 11288-93. (Pubitemid 44156511)
140. 1- adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics 2007; 17: 941-9. (Pubitemid 350293794)
141. Terra SG, Pauly DF, Lee CR,. β-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clinical Pharmacology and Therapeutics 2005; 77: 127-37. (Pubitemid 40269128)
142. Kaye DM, Smirk B, Williams C, et al., β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13: 379-82. (Pubitemid 36900732)
143. 2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. Journal of the American Medical Association 2005; 294: 1526-33. (Pubitemid 41362690)
144. 1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to β-blocker therapy in heart failure. Pharmacogenetics and Genomics 2007; 17: 277-82. (Pubitemid 46668051)
145. 2- adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. American Journal of Cardiology 2007; 99: 250-5. (Pubitemid 46072763)
146. Sehnert AJ, Daniels SE, Elashoff M, et al., Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. Journal of the American College of Cardiology 2008; 52: 644-51.
147. Johnson JA, Liggett SB,. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clinical Pharmacology and Therapeutics 2011; 89: 366-78.
148. Shin J, Johnson JA,. Beta-blocker pharmacogenetics in heart failure. Heart Failure Reviews 2010; 15: 187-96.
149. Dorn GW II,. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiological Reviews 2010; 90: 1013-62.
150. 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-64.
151. 2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure. BMC Cardiovascular Disorders 2009; 9: 50.
152. Dorn GW II, Liggett SB,. Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Molecular Pharmacology 2009; 76: 466-80.
153. Azuma J, Nonen S,. Chronic heart failure: β-blockers and pharmacogenetics. European Journal of Clinical Pharmacology 2009; 65: 3-17.
154. Muthumala A, Drenos F, Elliott PM, et al., Role of β adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. European Journal of Heart Failure 2008; 10: 3-13.
155. 2-adrenergic receptor expression and regulation phenotypes. PLoS One 2010; 5: e11819.
156. Metra M, Covolo L, Pezzali N, et al., Role of β-adrenergic receptor gene polymorphisms in the long-term effects of β-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs Therapeutics 2010; 24: 49-60.
157. Cresci S, Kelly RJ, Cappola TP, et al., Clinical and genetic modifiers of long-term survival in heart failure. Journal of the American College of Cardiology 2009; 54: 432-44.
158. Kitsios GD, Zintzaras E,. Synopsis and data synthesis of genetic association studies in hypertension for the adrenergic receptor family genes: the CUMAGAS-HYPERT database. American Journal of Hypertension 2010; 23: 305-13.
159. Goldstein DB,. Common genetic variation and human traits. New England Journal of Medicine 2009; 360: 1696-8.
160. 1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with
161. Pacanowski MA, Gong Y, Cooper-Dehoff RM, et al., β-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clinical Pharmacology and Therapeutics 2008; 84: 715-21.
162. 2-adrenoceptor polymorphisms in heart failure: a case-control study. European Heart Journal 2004; 25: 1534-41. (Pubitemid 39165632)
163. 1- adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to β-blocker therapy. American Journal of Cardiology 2008; 102: 726-32.
164. 1-adrenergic receptor gene results in haplotype-specific expression phenotypes. Journal of Cardiovascular Pharmacology 2008; 51: 106-10.
165. Zaugg M, Bestmann L, Wacker J, et al., Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiology 2007; 107: 33-44. (Pubitemid 46987817)
166. Ormond KE, Wheeler MT, Hudgins L, et al., Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375: 1749-51.
167. Ashley EA, Butte AJ, Wheeler MT, et al., Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-35.